サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1773190

淋病治療薬市場：感染タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Gonorrhea Therapeutics Market Assessment, By Infection Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 232 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
淋病治療薬市場：感染タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年07月21日
発行: Markets & Data
ページ情報: 英文 232 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の淋病治療薬の市場規模は、予測期間の2025年～2032年に4.43%のCAGRで拡大し、2024年の16億7,000万米ドルから2032年には23億6,000万米ドルに成長すると予測されています。製品開発、検査室診断、政府が支援する公衆衛生の取り組みが、主に淋病治療薬市場を牽引しています。淋病治療薬市場は、淋菌の経験的な抗生物質耐性の増加に伴う世界の淋病感染の最近の復活から急速にシフトしているが、このシフトは主に、淋病が世界的に最も一般的なSTIの1つであるという事実に起因しています。

ベルザトラリン、ゲポチダシン、ゾリフロダシンなどのパイプライン候補が、第一選択の抗生物質に対する耐性を克服する上で真に有望であることを示しています。これは、耐性菌の進化を追及することを目的とした代替療法をめぐる競争の大きな転換を意味します。

パンデミック後のヘルスケア・インフラの継続的な進歩に加え、公衆衛生資金の増加や政府の支援政策が、診断薬や治療薬へのアクセスを向上させ、市場の継続的な成長を後押ししています。しかし、特に感染負担の大きい地域では、このことが依然として治療への大きな制約となっています。

例えば、2025年5月、イングランド国民保健サービス（NHS）は、英国保健安全保障局（UKHSA）および地方自治体との提携を発表しました。淋病予防のための世界初のワクチンプログラムを実施しました。この介入は、4CMenB（Bexsero）ワクチン（もともとは髄膜炎Bのために開発された）を使用し、淋菌に対する既知の交差防御を提供するもので、抗生物質耐性に対処し、淋病の世界的負担に対処する上で重要な進歩です。

当レポートでは、世界の淋病治療薬市場について調査し、市場の概要とともに、感染タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の淋病治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 感染タイプ別
      • 泌尿生殖器淋病
      • 性器外淋病
      • 播種性淋菌感染症（DGI）
      • 周産期/新生児淋病
    • 治療タイプ別
      • 単剤療法
      • 併用療法
    • 投与経路別
      • 経口薬
      • 注射
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米の淋病治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の淋病治療薬市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の淋病治療薬市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の淋病治療薬市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの淋病治療薬市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制の枠組み

  • 臨床試験
  • 規制当局の承認

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • AstraZeneca
    • Innoviva, Inc. (Innoviva Specialty Therapeutics, Inc.)
    • Debiopharm International SA
    • TherapyX Inc.
    • Recce Pharmaceuticals Ltd
    • Evofem Biosciences, Inc.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 3. Global Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 4. Global Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Gonorrhea Therapeutics Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 9. North America Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 10. North America Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 11. North America Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Gonorrhea Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 15. United States Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 16. United States Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 17. United States Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 20. Canada Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 21. Canada Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Canada Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 25. Mexico Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 26. Mexico Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 27. Mexico Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 30. Europe Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 31. Europe Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Europe Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Gonorrhea Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 36. Germany Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 37. Germany Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Germany Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 41. France Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 42. France Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. France Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 46. Italy Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 47. Italy Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 48. Italy Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 51. United Kingdom Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 52. United Kingdom Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 53. United Kingdom Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 56. Russia Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 57. Russia Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 58. Russia Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 61. Netherlands Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 62. Netherlands Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Netherlands Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 66. Spain Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 67. Spain Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 68. Spain Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 71. Turkey Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 72. Turkey Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 73. Turkey Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 76. Poland Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 77. Poland Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Poland Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. South America Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 81. South America Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 82. South America Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 83. South America Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. South America Gonorrhea Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 87. Brazil Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 88. Brazil Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. Brazil Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Argentina Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 92. Argentina Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 93. Argentina Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 94. Argentina Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Asia-Pacific Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 97. Asia-Pacific Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 98. Asia-Pacific Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. Asia-Pacific Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Asia-Pacific Gonorrhea Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 101. India Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 103. India Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 104. India Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 105. India Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. China Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 108. China Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 109. China Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 110. China Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 111. Japan Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 113. Japan Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 114. Japan Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 115. Japan Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 116. Australia Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 118. Australia Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 119. Australia Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 120. Australia Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 121. Vietnam Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 123. Vietnam Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 124. Vietnam Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. Vietnam Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. South Korea Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 128. South Korea Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 129. South Korea Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Korea Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. Indonesia Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 133. Indonesia Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 134. Indonesia Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 135. Indonesia Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Philippines Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 138. Philippines Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 139. Philippines Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 140. Philippines Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 143. Middle East & Africa Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 144. Middle East & Africa Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 145. Middle East & Africa Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Gonorrhea Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 149. Saudi Arabia Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 150. Saudi Arabia Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. Saudi Arabia Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 154. UAE Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 155. UAE Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 156. UAE Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Gonorrhea Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Gonorrhea Therapeutics Market Share (%), By Infection Type, 2018-2032F
  • Figure 159. South Africa Gonorrhea Therapeutics Market Share (%), By Treatment Type, 2018-2032F
  • Figure 160. South Africa Gonorrhea Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. South Africa Gonorrhea Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Infection Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13697

Global gonorrhea therapeutics market is projected to witness a CAGR of 4.43% during the forecast period 2025-2032, growing from USD 1.67 billion in 2024 to USD 2.36 billion in 2032. Product development, laboratory diagnostics, and government-supported public health initiatives primarily drive the gonorrhea therapeutics market. While the gonorrhea therapeutics market is rapidly shifting, in part from the recent resurgence of gonorrhea infection worldwide with increasing empirical antibiotic resistance of Neisseria gonorrhoeae, this shift is attributed mainly to the fact that gonorrhea is one of the most common STIs worldwide.

The gonorrhea therapeutics market is riding an exciting wave of pharmaceutical innovation on the therapeutic side, with several pipeline candidates, such as verzatraline, gepotidacin, and zoliflodacin, showing real promise in overcoming resistance to first-line antibiotics. This represents a significant shift in the race for alternative therapies aimed at pursuing resistance as it evolves.

Increased public health funding and supportive government policy, along with continued advancements in healthcare infrastructure following a pandemic business cycle, are driving continued market growth by providing more access to diagnostics and therapeutics. However, this remains a significant limitation to care, particularly in geographic areas with a greater burden of infection.

For instance, in May 2025, the National Health Service (NHS) England announced a partnership with the UK Health Security Agency (UKHSA) and local government. It undertook a world-first vaccine programme to prevent gonorrhea. This intervention uses the 4CMenB (Bexsero) vaccine (developed originally for meningitis B) to provide known cross-protection against Neisseria gonorrhoeae, which is a significant advancement in addressing antibiotic resistance and addressing the global burden of gonorrhea.

Role of Drug Innovation Expands the Global Gonorrhea Therapeutics Market Size

The gonorrhea therapeutics market is driven by drug innovation and the inherent ability to rapidly bring drugs to market, given the threat posed by antibiotic-resistant Neisseria gonorrhoeae. As the effectiveness of standard treatment options diminishes, it has compelled the pharmaceutical industry and related research institutions to develop new therapies with novel mechanisms of action that either inhibit or reduce N. gonorrhoeae growth or morbidity rates. This type of research advances clinical gaps and expands opportunities in the market by developing treatments that are potentially safer, more effective, easier to access, or easier for patients to use as potential therapies. An area of considerable potential is the use of oral antibiotics (in place of or in addition to any injectable treatment), which will increase access for patients in both high- and low-income countries.

For instance, in March 2025, GlaxoSmithKline (GSK) gained US FDA approval for Blujepa (gepotidacin) for uncomplicated urinary tract infections in females aged 12 years and older.

Diagnostic Innovations Drives Global Gonorrhea Therapeutics Market Growth

Innovations in diagnostic technologies are generating a significant increase in the Gonorrhea Therapeutics market through the ability to simplify the early and accurate detection of Neisseria gonorrhoea infections. Examples of innovations include nucleic acid amplification tests (NAATs), point-of-care molecular assays, and multiplex diagnostics, which have significantly enhanced the sensitivity and specificity of diagnosis, enabling clinicians to identify infections in asymptomatic cases. Early diagnostics would allow patients to access appropriate, targeted antibiotic therapies more quickly, leading to improvements in patient outcomes using antibiotics in any given prescribing regimen. This exact early identification of infection by the clinician can help break chains of transmission to other patients or even the public it serves. These improved diagnostics further enable detailed antimicrobial susceptibility profiling of Neisseria gonorrhoeae isolates, as this becomes increasingly critical to our understanding of the emergence rate of multidrug-resistant gonococcal strains of bacteria. The advancement of diagnostic technology into clinical and public health systems can facilitate more effective management plans and help stimulate the development and uptake of alternative therapeutics in the gonorrhea treatment market.

For instance, in March 2025, the United States Food and Drug Administration (FDA) granted marketing authorization for the first at-home diagnostic test for Chlamydia, Gonorrhea, and Trichomoniasis, marking an important milestone in the regulatory process for home STI testing solutions through the 510(k) pathway.

Combination Therapy Dominates the Global Gonorrhea Therapeutics Market Share

The combination therapy type in the gonorrhea therapeutics market is the fastest growing. The dual antibiotic regime using ceftriaxone with azithromycin has become the standard of care due to its effectiveness against Neisseria gonorrhoeae infections, including those strains resistant to single antibiotic therapy. Combination therapy reduces the potential for the development of resistance by using more than one mechanism to target the bacteria simultaneously. There are multiple drivers of market growth for this therapy type, including the global increase in gonorrhea, driven by the urgent need to address the rising antibiotic resistance. As a specific illustration, the recently published guidelines regarding the treatment of gonorrhea by the Centers for Disease Control and Prevention (CDC) still advocate dual therapy as the frontline for the treatment of gonorrhea, suggesting the proliferation of its use in the world. Additionally, the recent launch of an oral antibiotic, zoliflodacin, will further advance the trend toward combination therapy, as it can be used in combination with other antibiotics or as an alternative to single antibiotic therapy, thereby changing the strategy for treating gonorrhea infections by including multiple drugs.

For instance, from November 2019 to August 2023, the Global Antibiotics Research and Development Partnership conducted a multi-center, randomized, open-label, non-inferiority trial to evaluate the efficacy and safety of a single oral dose of zoliflodacin compared to a combination of a single intramuscular dose of ceftriaxone and a single oral dose of azithromycin in the treatment of patients with uncomplicated gonorrhea. This study demonstrated that zoliflodacin was effective and safe, offering a promising alternative therapy against antibiotic-resistant gonorrhea.

North America Dominates the Global Gonorrhea Therapeutics Market Size

North America is leading the Gonorrhea therapeutics market based on key elements. Firstly, there is a high prevalence of Gonorrhea infections in North America, which adds to the demand for therapeutics. The advanced healthcare infrastructure and access to medical institutions provide opportunities for timely diagnosis and the implementation of therapeutics. There are also considerable government initiatives and public health direction on sexually transmitted infections, which give more awareness and direction on screening and management. There are also significant investments in research and development by pharmaceutical companies in North America, which fosters greater innovation and the development of new therapeutics to treat the resilient strains. Ultimately, North America boasts a favorable regulatory framework for gonorrhea therapeutics, alongside higher healthcare spending, which will continue to position it at the forefront of the gonorrhea therapeutics market.

For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC) 2023 STI Surveillance Report, the United States reported 601,319 cases of gonorrhea, reflecting both the high disease burden and the active healthcare response driving demand for new and effective treatments.

Impact of U.S. Tariffs on Global Gonorrhea Therapeutics Market

Increased Production Costs: Tariffs on imported materials cause an increase in costs for companies that produce medication for gonorrhea treatment.

Higher Patient Costs: Increased costs for companies create a result that most medications are more expensive; this could make medications to treat infections more prohibitive at the patient level.

Delays and Shortages: Tariffs create interruptions in the supply chains, which may cause delays or shortages of essential medications.

Less Competition: Higher costs may lead to smaller companies struggling to compete in or enter the market.

More Local Manufacturing: To work around tariffs, companies may start up drug production facilities closer to home; this change could impact the functioning of the global market.

Key Players Landscape and Outlook

The global gonorrhea therapeutics market is rapidly shifting as the pharmaceutical market is reacting to the need for options associated with increased antibiotic resistance. Many major pharmaceutical companies are developing novel therapies, including new antibiotics and enhanced combination therapies. GlaxoSmithKline plc is developing gepotidacin, while Innoviva Specialty Therapeutics, Inc is developing zoliflodacin, both oral alternatives to injectable treatments, which provide better convenience, as well as the opportunity to limit the spread of resistant strains of Neisseria gonorrhoeae. All this activity reflects the collaborative and coordinated initiative by pharmaceutical innovation, generics, and diagnostics to tackle one of the most prevalent sexually transmitted infections in the world. The next step involves the development and approval of a new therapy for prescribers and patients, which is critical to positively transforming and enhancing patient outcomes.

For instance, in June 2025, Innoviva Specialty Therapeutics received FDA acceptance of its New Drug Application for zoliflodacin, a first-in-class oral antibiotic for the treatment of uncomplicated gonorrhea in adults.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Infection Type
      • 5.2.1.1. Urogenital Gonorrhea
      • 5.2.1.2. Extragenital Gonorrhea
      • 5.2.1.3. Disseminated Gonococcal Infection (DGI)
      • 5.2.1.4. Perinatal/Neonatal Gonorrhea
    • 5.2.2. By Treatment Type
      • 5.2.2.1. Monotherapy
      • 5.2.2.2. Combination Therapy
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral Medications
      • 5.2.3.2. Injectable Therapies
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Infection Type
    • 5.3.2. By Treatment Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Infection Type
      • 6.2.1.1. Urogenital Gonorrhea
      • 6.2.1.2. Extragenital Gonorrhea
      • 6.2.1.3. Disseminated Gonococcal Infection (DGI)
      • 6.2.1.4. Perinatal/Neonatal Gonorrhea
    • 6.2.2. By Treatment Type
      • 6.2.2.1. Monotherapy
      • 6.2.2.2. Combination Therapy
    • 6.2.3. By Route of Administration
      • 6.2.3.1. Oral Medications
      • 6.2.3.2. Injectable Therapies
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Hospital Pharmacies
      • 6.2.4.2. Retail Pharmacies
      • 6.2.4.3. Online Pharmacies
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Gonorrhea Therapeutics Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Infection Type
          • 6.3.1.2.1.1. Urogenital Gonorrhea
          • 6.3.1.2.1.2. Extragenital Gonorrhea
          • 6.3.1.2.1.3. Disseminated Gonococcal Infection (DGI)
          • 6.3.1.2.1.4. Perinatal/Neonatal Gonorrhea
        • 6.3.1.2.2. By Treatment Type
          • 6.3.1.2.2.1. Monotherapy
          • 6.3.1.2.2.2. Combination Therapy
        • 6.3.1.2.3. By Route of Administration
          • 6.3.1.2.3.1. Oral Medications
          • 6.3.1.2.3.2. Injectable Therapies
        • 6.3.1.2.4. By Distribution Channel
          • 6.3.1.2.4.1. Hospital Pharmacies
          • 6.3.1.2.4.2. Retail Pharmacies
          • 6.3.1.2.4.3. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Gonorrhea Therapeutics Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. F. Hoffmann-La Roche Ltd
    • 21.3.3. GlaxoSmithKline plc
    • 21.3.4. Merck & Co., Inc.
    • 21.3.5. AstraZeneca
    • 21.3.6. Innoviva, Inc. (Innoviva Specialty Therapeutics, Inc.)
    • 21.3.7. Debiopharm International SA
    • 21.3.8. TherapyX Inc.
    • 21.3.9. Recce Pharmaceuticals Ltd
    • 21.3.10. Evofem Biosciences, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer